Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Highly Accessed Research article

Burden of rotavirus gastroenteritis in the Middle Eastern and North African pediatric population

Hanane Khoury1*, Isla Ogilvie1, Antoine C El Khoury2, Yinghui Duan3 and Mireille M Goetghebeur1

Author Affiliations

1 BioMedCom Consultants inc., 1405 TransCanada Highway, Suite 310, Montreal, Quebec, H9P 2V9, Canada

2 Merck & Co, West Point, PA, 19486, USA

3 Lehigh University, Bethlehem, PA, 18015, USA

For all author emails, please log on.

BMC Infectious Diseases 2011, 11:9  doi:10.1186/1471-2334-11-9

Published: 7 January 2011

Abstract

Background

Rotavirus gastroenteritis (RVGE) is the most common cause of severe childhood diarrhea worldwide. Objectives were to estimate the burden of RVGE among children less than five years old in the Middle East (Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, Syria, UAE, Yemen), North Africa (Algeria, Egypt, Libya, Morocco, Tunisia) and Turkey.

Methods

A comprehensive literature search was conducted in major databases on the epidemiology and burden of rotavirus among children less than five years old between 1999 and 2009. Data from each country was extracted and compared.

Results

The search identified 43 studies. RVGE was identified in 16-61% of all cases of acute gastroenteritis, with a peak in the winter. RVGE-related hospitalization rates ranged from 14% to 45%, compared to 14%-28% for non-RVGE. Annually, RVGE caused up to 112 fatalities per 100,000 in certain countries in the region. Hospitalization costs ranged from $1.8 to $4.6 million annually, depending on the country. The most recent literature available showed that G1P[8] was the most prevalent genotype combination in 8 countries (range 23%-56%). G2P[4] was most prevalent in 4 countries (26%-48%). G9P[8] and G4P[8] were also frequently detected.

Conclusions

RVGE is a common disease associated with significant morbidity, mortality, and economic burden. Given the variety and diverse rotavirus types in the region, use of a vaccine with broad and consistent serotype coverage would be important to help decrease the burden of RVGE in the Middle East and North Africa.